Navigation Links
Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
Date:1/6/2009

AMSTERDAM, January 6 /PRNewswire/ -- Biopharmaceutical Company Kiadis Pharma focused on the development of innovative cell based therapeutics in the field of bone marrow transplantation, announces today the appointment of Dr. Maarten Egeler as Chief Medical Officer (CMO). Dr. Egeler is a global leading pediatric bone marrow transplantation physician and an internationally-recognized authority in pediatric hemato-oncology. He brings to Kiadis Pharma over more than 20 years of expertise in this field.

The appointment of Dr. Egeler is an important milestone in the development of Kiadis Pharma's lead product ATIR(TM) as a revolutionary approach to provide safe and potentially life-saving mismatched bone marrow transplantations as a treatment option for end-stage leukemia patients. Dr. Egeler's appointment will strongly support the upcoming multi-center pivotal study on ATIR(TM) early 2009.

Dr. Egeler will join Kiadis Pharma part time next to his position as Head of the Pediatric Oncology and Bone Marrow Transplantation division of the University of Leiden. As Kiadis Pharma's CMO, he will oversee all medical affairs of the company and he will work closely with the company's global network of key opinion leaders in the transplantation community on the development of the company's products.

"Maarten has been acting as a medical advisor for Kiadis Pharma over the last year and we are very pleased that he agreed to become our CMO", says Manja Bouman, CEO of Kiadis Pharma. "The depth of his medical expertise in the field of bone marrow transplantations, his leadership worldwide in haplo-identical transplantation and his network with key opinion leaders in the field will greatly contribute to the success of our products and company".

"I am very excited to join Kiadis Pharma in the role of CMO. I look forward to participate in the development of its programs. I am particularly excited to w
'/>"/>

SOURCE Kiadis Pharma
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
5. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
6. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
7. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
8. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
9. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)CALGARY, Dec. 2 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics" or the "Company") (TSX:ONC; NASDAQ: ONCY ) announced today that in connection with its previously announced unit offering
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
(Date:12/2/2009)RESTON, Va., Dec. 2 /PRNewswire-Asia-FirstCall/ -- Emerald Dairy, Inc.,("Emerald Dairy" or the "Company") (OTC Bulletin Board: EMDY), a leading,producer and distributor of infant and children,s formul
(Date:12/2/2009)SHANGHAI, Dec. 2 /PRNewswire-Asia/ -- The world is going through,extraordinary times; markets are in turmoil and uncertainty is part of many,businesses and industries. It turns out that the pharma ind
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3Emerald Dairy To Be Featured in Spring Issue of US Food and Drink Executive 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 2Pharma and Biotech Leaders to Converge in China at Asia Pharma R&D Leaders 2010 Summit 3
..., April 15 /PRNewswire-Asia/ -- AgFeed Industries,...roduction and animal nutrient companies in China, ...arrangement with Hypor, a Hendrix Genetics Company... superior swine genetics and technology. Hypor has... one of the world,s largest broad-based breeding p...
... Customers Can Claim A Free Introd...Your Organization,s Resilience in the Downturn&quo....html , San Francisco, C... Mariposa Leadership, Inc. announces the kick-off ... to provide business leaders, managers, and execut...
...HERFORD, N.J., April 14 Cambrex Corporation (NYSE...n notified by the New York Stock Exchange (the "NY...g standard relating to the Company,s total market ...Company received the notice on April 9, 2009 from ...g standards because its average market capitalizat...
Other Biology Technology:AgFeed Industries Enters Into Hog Genetic Program Arrangement with Hypor, the Pig Breeding Division of Hendrix Genetics B.V. 2AgFeed Industries Enters Into Hog Genetic Program Arrangement with Hypor, the Pig Breeding Division of Hendrix Genetics B.V. 3AgFeed Industries Enters Into Hog Genetic Program Arrangement with Hypor, the Pig Breeding Division of Hendrix Genetics B.V. 4Executive Coaching Firm Mariposa Leadership, Inc. Hosts Webinar to Help Business Leaders Navigate Tumultuous Economy 2Cambrex Receives Notice Regarding NYSE Listing 2Cambrex Receives Notice Regarding NYSE Listing 3
(Date:12/3/2009)A coating on windows or solar panels that repels grime and dirt? Expanded battery storage capacities for the next electric car? New Tel Aviv University research, just published in Nature Nanotechnolo
(Date:12/3/2009)Coral reef fish can undergo a personality change in warmer water, according to an intriguing new study suggesting that climate change may make some species more aggressive. , Experiments with two spe
(Date:12/3/2009)UPTON, NY A team of scientists from the U.S. Department of Energy,s (DOE) Brookhaven National Laboratory, Harvard University, and the Indian Institute of Science has made a major step in understandin
Breaking Biology News(10 mins):A window that washes itself? 2Fish with attitude: Some like it hot 2Grooving down the helix 2Grooving down the helix 3Viral Genetics Responds to Rumors of Imminent FDA Filing and Third Party Press Releases 13699 1Viral Genetics Responds to Rumors of Imminent FDA Filing and Third Party Press Releases 13699 2Viral Genetics Responds to Rumors of Imminent FDA Filing and Third Party Press Releases 13699 3Gene Fix in Egg Prevents Inherited Diseases in Monkeys 55432 1Gene Fix in Egg Prevents Inherited Diseases in Monkeys 55432 2Gene Fix in Egg Prevents Inherited Diseases in Monkeys 55432 3Home Delivery Medical Launches New Division For Sleep Centers 55431 1Home Delivery Medical Launches New Division For Sleep Centers 55431 2Home Delivery Medical Launches New Division For Sleep Centers 55431 3
...adcasts have long been a staple for people plannin... researchers are working to broaden daily forecast...at is becoming reality in some parts of the world....stem of routine, global forecasts of air pollution...s only a few years away. Such a system could prove...
...Conn. A before-and-after study led by Yale biolog... diversity of marine iguanas on the Galpagos Islan...ons over time and the need to determine which envi...ulations more vulnerable than others. , According...n ideal system to study the impact of human-mediat...
...Ill. Using computer simulations, researchers at t...tegy for sequencing DNA by driving the molecule ba...iconductor chip. The technique could lead to a dev...rdably., Being able to sequence a human genome for... companies are willing to pay) could open a new er...
Other Biology News:Air quality forecasts see future in space 2Air quality forecasts see future in space 3Global climate change: The impact of El Nio on Galpagos marine iguanas 2New technique could dramatically lower costs of DNA sequencing 2
Mouse Anti-Cystatin A Monoclonal Antibody, Unconjugated, Clone WR-23/2/3/3 from Sigma-Aldrich
Human COX-2 ELISA Kit from Invitrogen
...lding on the ease of use and flexibility of the BD...nces introduces the BDTM LSR II. The BD LSR II ha... seen before in a benchtop analyzer. Free up your...cation(s) that require a UV laser to the BD LSR II...
... Mini-PROTEAN II multiscreen apparatus is used to ...pparatus can screen up to 40 different antibodies .... The apparatus includes a base plate, 2 separate,...or two 8 x 7 cm membranes, and gaskets and clamps ...
Biology Products: